최고 Haematology 팟캐스트 (2024)

1
Chronic Monomyelocytic Leukemia (CMML) 41:56

4d ago41:56

41:56

Chronic MyeloMonocytic Leukemia (not CML) Persistently high monocyte count- 3 months Most frequent MDS/Myeloproliferative neoplasms – a cross between the two Median age 72 Median survival 20-40 months Transformation to AML (15-30%) WHO definition of CMML: 1. Excess monocytes- persistent over 3 months, ≥ 1 - Monocytes 10% of total WC count 2. Dyspla…

1
Chronic Lymphocytic Leukemia (CLL) 1:18:33

18d ago1:18:33

1:18:33

Chronic Lymphocytic Leukemia (CLL)- Chronic Relapsing Remitting Most common leukemia in adults Incurable but treatable *Remember Supportive Care* Median age of 72 M > F 80% incidental SLL: lymphocytes in lymph nodes and spleen instead of blood Presentation: 1) Fatigue 2) B symptoms 3) High WC 4) Cytopenias (Marrow infiltrate, AIHA, ITP, Hyposplenis…

1
In conversation with... Sabine Braat and Katherine Fielding 18:06

2M ago18:06

18:06

Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia.저자 The Lancet

1
Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia 18:06

2M ago18:06

18:06

Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00030-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https:…

1
Elisabeth Schorb on the MARTA phase 2 trial 9:23

2M ago9:23

9:23

Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00371-X/fulltext?dgcid=buzzsprout_icw_podcast…

1
In conversation with... Elisabeth Schorb 9:23

2M ago9:23

9:23

Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation.저자 The Lancet

1
In conversation with... Stephan Ehl 13:03

3M ago13:03

13:03

Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.저자 The Lancet

1
Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies 13:03

3M ago13:03

13:03

Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Continue this conversation on social! Follow us today at..…

1
In conversation with... Sarah O'Brien 13:50

4M ago13:50

13:50

Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma.저자 The Lancet

1
Dr Sarah O'Brien on the PREVAPIX-ALL trial 13:50

4M ago13:50

13:50

Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma. Read the full article: https://www.thelancet.com/journal…

1
In conversation with... Enrico Lopriore 12:33

5M ago12:33

12:33

Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn.저자 The Lancet

1
Enrico Lopriore on haemolytic disease of the fetus and newborn 12:33

5M ago12:33

12:33

Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00285-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on …

1
In conversation with... Meletios Dimopoulos

7M ago

—

Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial.저자 The Lancet

1
Meletios Dimopoulos on relapsed and refractory multiple myeloma 11:00

7M ago11:00

11:00

Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcas…

1
In conversation with... Eric Ohuma 16:27

8M ago16:27

16:27

Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes.저자 The Lancet

1
Eric Ohuma on haemoglobin concentrations and neonatal outcomes 16:27

8M ago16:27

16:27

Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continu…

1
In conversation with... Margaret Ragni 13:13

9M ago13:13

13:13

Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA.…

1
Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding 13:13

9M ago13:13

13:13

Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. Read the full article: https://www.th…

1
In conversation with... Oreofe Odejide and Thomas Kuczmarski 16:32

10M ago16:32

16:32

Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.저자 The Lancet

1
Oreofe Odejide and Thomas Kuczmarski on mental health and lymphoma 16:32

10M ago16:32

16:32

Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_gen…

1
In conversation with... Alok Srivastava 18:41

1y ago18:41

18:41

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.저자 The Lancet

1
Alok Srivastava on fitusiran for patients with haemophilia A and B 18:41

1y ago18:41

18:41

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B. Read the two trials: Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH) https://www.t…

1
Emmanuela E Ambrose on stroke prevention in children with sickle cell disease 11:31

1y ago11:31

11:31

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania Read the full article: Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE) Continue this conversation on social!…

1
In conversation with... Emmanuela E Ambrose 11:31

1y ago11:31

11:31

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania저자 The Lancet

1
Sumit Gupta on racial and ethnic disparities in leukaemia survival outcomes 22:10

1y ago22:10

22:10

Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia. Read the full article: Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia Continue this conversation on social! Follow us today at... https://twitter.com/thelancet htt…

1
In conversation with... Sumit Gupta 22:10

1y ago22:10

22:10

Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia.저자 The Lancet

1
In conversation with... Xiao-Jun Huang 28:10

1+ y ago28:10

28:10

Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China.저자 The Lancet

1
Xiao-Jun Huang on cellular therapy in China 28:10

1+ y ago28:10

28:10

Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China. Read the Series papers: Cellular therapy in China Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://i…

1
Glenn Pierce on haemophilia care in LMICs 34:55

1+ y ago34:55

34:55

Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries. Read the full Review: Achieving access to haemophilia care in low-income and lower-middle-income countries Continue this conversation on social! Follow us today at... http…

1
In conversation with... Glenn Pierce 34:55

1+ y ago34:55

34:55

Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries.저자 The Lancet

1
Amy DeZern on the link between myelodysplastic syndrome and autoimmune disorders 12:50

2y ago12:50

12:50

Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both. Read the full article: Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Continue this conversation on social! Follow us today at... https:…

1
In conversation with... Amy DeZern 12:50

2y ago12:50

12:50

Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both.저자 The Lancet

1
In conversation with... Nicholas Crombie and Gavin Perkins 15:05

2y ago15:05

15:05

Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care.저자 The Lancet

1
Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline 15:05

2y ago15:05

15:05

Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://inst…

1
In conversation with... Fredrik Schjesvold 12:24

2y ago12:24

12:24

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide.저자 The Lancet

1
Fredrik Schjesvold on OCEAN phase 3 12:24

2y ago12:24

12:24

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide. Read the full article: Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN) Continue this conversatio…

1
Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia 11:59

2+ y ago11:59

11:59

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext Continu…

1
In conversation with... Jacob D Soumerai and Andrew D Zelenetz 11:59

2+ y ago11:59

11:59

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.저자 The Lancet

1
Raul Cordoba on haematological malignancies in older people 16:24

2+ y ago16:24

16:24

Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people. Read the full article: A comprehensive approach to therapy of haematological malignancies in older patients Continue this conversation on social! Follow us today at... https://twitter.com/thelanc…

1
In conversation with... Raul Cordoba 16:24

2+ y ago16:24

16:24

Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people.저자 The Lancet

1
In conversation with…Obiageli Nnodu and Dennis Chao 9:03

2+ y ago9:03

9:03

Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria.저자 The Lancet

1
Obiageli Nnodu and Dennis Chao on child mortality from sickle cell disease in Nigeria 9:03

2+ y ago9:03

9:03

Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00191-5/fulltext Continue this conversation on social! Follo…

1
In conversation with... Dr Zuguo Mei and Dr Gary M Brittenham 8:34

2+ y ago8:34

8:34

Dr Zuguo Mei and Dr Gary M Brittenham talk about their work defining physiologically based serum ferritin thresholds for iron deficiency.저자 The Lancet

1
Zuguo Mei and Gary Brittenham on iron deficiency 8:34

2+ y ago8:34

8:34

Senior Assistant Editor Ben Burwood speaks with Dr Zuguo Mei (Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA) and Dr Gary M Brittenham (Department of Pediatrics, College of Physicians and Surgeons, Columbia Unive…

1
Eugenia Trigoso Arjona (in Spanish) on nursing and haematological care 29:11

3y ago29:11

29:11

Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología. C…

1
Eugenia Trigoso Arjona (in English) on nursing and haematological care 28:34

3y ago28:34

28:34

To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care. Continue thi…

1
In conversation with... Eugenia Trigoso Arjona (in Spanish)

3y ago

—

Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología.…

1
In conversation with... Eugenia Trigoso Arjona (in English) 28:34

3y ago28:34

28:34

To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care.…

1
Nada Hamad on inclusion and diversity in haematology 30:02

3y ago30:02

30:02

A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljourna…

1
In Conversation With… Nada Hamad 30:03

3y ago30:03

30:03

A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation.저자 The Lancet

들어볼 가치가 있는 팟캐스트

Haematology 팟 캐스트

들어볼 가치가 있는 팟캐스트

빠른 참조 가이드